Stockscreener 앱 받기
1.05
12.61%
0.1176
시장 영업 전:
1.07
0.02
+1.90%
Jasper Therapeutics Inc 주식(JSPR)의 최신 뉴스
Jasper Shares Surge Following Encouraging Early Asthma Trial Data - MSN
Jasper Therapeutics shares rise 5% on clinical updates despite Q4 loss - MSN
Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7 - Insider Monkey
JSPR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
12 Health Care Stocks Moving In Thursday's After-Market SessionBullfrog AI Hldgs (NASDAQ:BFRG), CDT Eq - Benzinga
Why UBS started Jasper Therapeutics (JSPR) at neutral despite progress in briquilimab - MSN
UBS Maintains Jasper Therapeutics(JSPR.US) With Hold Rating, Maintains Target Price $1.5 - Moomoo
Jasper Therapeutics price target lowered to $7 from $12 at Evercore ISI - TipRanks
Citizens reiterates Jasper Therapeutics stock rating on CEO change By Investing.com - Investing.com Australia
Citizens reiterates Jasper Therapeutics stock rating on CEO change - Investing.com
Jasper Therapeutics’ Deep Cuts May Backfire: Analyst Warns Downsizing Could Undermine Briquilimab Strategy and Cash Runway - TipRanks
Jasper Therapeutics stock gains 5% on clinical progress despite Q4 loss - Investing.com India
MINISO Group Holding Limited (MNSO) Reports Q4 Earnings - news.alphastreet.com
Jasper Therapeutics, Inc. (JSPR) Reports Q4 Earnings - AlphaStreet
Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update - Bitget
Jasper Therapeutics reports Q4 EPS (32c), consensus (82c) - TipRanks
Jasper Therapeutics (JSPR) 10-K focuses on briquilimab mast cell programs and funding needs - Stock Titan
JSPR: Strong clinical progress but increased net loss and lower cash reserves highlight funding needs - TradingView — Track All Markets
Jasper Therapeutics (NASDAQ: JSPR) posts $75.8M 2025 loss, cash at $28.7M - Stock Titan
Jasper Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Jasper Therapeutics 4Q Loss $9.1M >JSPR - moomoo.com
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Jasper Therapeutics (JSPR) price target decreased by 30.92% to 8.92 - MSN
Analysts Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Target Price at $19.88 - Defense World
Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab - Yahoo Finance
Jasper Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
10 Penny Stocks with Potential to Rise 1000 Percent - Insider Monkey
JSPR Stock Price, Quote & Chart | JASPER THERAPEUTICS INC (NASDAQ:JSPR) - ChartMill
Jasper Therapeutics Inc (JSPR) Stock News & Articles - 24/7 Wall St.
Jasper Therapeutics stock surges on positive briquilimab trial data amid mast cell therapy race - AD HOC NEWS
UBS Downgrades Jasper Therapeutics To Neutral From Buy, Cuts Price Target to $1.5 From $25 - marketscreener.com
UBS initiates Jasper Therapeutics stock rating at Neutral on competition By Investing.com - Investing.com Canada
UBS initiates Jasper Therapeutics stock rating at Neutral on competition - Investing.com
If You Invested $1,000 in Jasper Therapeutics Inc (JSPR) - Stock Titan
Jasper Therapeutics stock surges on positive briquilimab trial data for mast cell diseases - AD HOC NEWS
JSPR Should I Buy - Intellectia AI
Jasper Therapeutics, Inc. (JSPRW) Competitors - Meyka
Jasper Therapeutics (JSPR) Price Target Decreased by 15.25% to 13.09 - MSN
How Jasper Therapeutics Inc. stock compares to industry benchmarksQuarterly Portfolio Review & Weekly High Return Forecasts - Naître et grandir
Aug Opening: How Jasper Therapeutics Inc. stock compares to industry benchmarksJuly 2025 Snapshot & Pattern Based Trade Signal System - Naître et grandir
Jasper Therapeutics, Inc. (JSPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Jasper Therapeutics, Inc. (JSPR) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
2.69%
0.25%
자본화:
|
볼륨(24시간):